KR900017581A - α-아미노보론산 유도체를 함유하는 펩티드-약제 조성물 - Google Patents

α-아미노보론산 유도체를 함유하는 펩티드-약제 조성물 Download PDF

Info

Publication number
KR900017581A
KR900017581A KR1019890006223A KR890006223A KR900017581A KR 900017581 A KR900017581 A KR 900017581A KR 1019890006223 A KR1019890006223 A KR 1019890006223A KR 890006223 A KR890006223 A KR 890006223A KR 900017581 A KR900017581 A KR 900017581A
Authority
KR
South Korea
Prior art keywords
peptide
pharmaceutical composition
protein
tyr
phe
Prior art date
Application number
KR1019890006223A
Other languages
English (en)
Inventor
알완 허사인 무니어
빅카파 쉔비 아쇽쿠마
Original Assignee
제임스 제이. 플린
이. 아이. 듀퐁 드 네모아 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 제이. 플린, 이. 아이. 듀퐁 드 네모아 앤드 캄파니 filed Critical 제임스 제이. 플린
Publication of KR900017581A publication Critical patent/KR900017581A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

α-아미노브론산 유도체를 함유하는 펩티드-약제 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 필수적으로, 약제학적으로 허용되는 담체, 단백질 또는 펩티드, 임의로는 흡수 증진제, 및 하기 일반식의 α-아미노보론산 유도체로 이루어진 약제학적 조성물.
    상기식에서, HW는 무기산, 설폰산, 알카노산 또는퍼플루오로알카노산이고, Y는 탄소원자 및, 임의로는 N,S 또는 O일수 있는 헤테로 원자를 함유하는 쇄 또는 환에서 두개 이상의 결합원자에 의해 분리된 하이드록시 그룹을 두개이상 함유하는 디하이드록시 화합물로부터 유도된 잔기이며, R은 알킬 또는 -CH2R1이고, R1은 -XR2,아릴 또는 하나이상의 알킬그룹으로 치환된 아릴이며, X는 O또는 S이고, R2는 -H,알킬 또는 -SiR3R4R5이며, R3,R4및 R5는 각각 알킬, 아릴, 또는 하나 이상의 알콕시그룹으로 치환된 아릴이다.
  2. 제1항에 있어서, 단백질 또는 펩티드 프로테아제에 의해 가수분될 수 있는 약제학적 조성물.
  3. 제2항에 있어서,단백질 또는 펩티드가 로이신 엔케팔린,LH-RH,Tyr-PHe-Met-Arg-Phe-NH2,Tyr-브레디키닌 및 티모포이에틴 Ⅱ로 이루어진 그룹중에서 선택되는 약제학적 조성물.
  4. 제1항에 있어서, Y가또는 -(CH2)2NH2(CH)2-인 약제학적 조성물.
  5. 제1항에 있어서, R이 -CH3, -CH(CH3)2, -CH2CH2(CH|3)2, CH(CH3)C2H5또는인 약제학적 조성물.
  6. 제1항에 있어서, HW가 CF3CO2H, CH3CO2H, Hcl 또는 HBr인 약제학적 조성물.
  7. 제1항에 있어서, α-아미노보론산 유도체가 3-메틸-1-(4,4,5,5-테트라메틸-1,3,2-디옥사보롤란-2-일-1-부타민, 트리플루오로아세트산염인 약제학적 조성물.
  8. 제1항에 있어서,경구투여에 적합한 투여형태인 약제학적 조성물.
  9. 제1항에 있어서, 경구투여에 적합한 투여형태인 약제학적 조성물
  10. 하기 일반식의 α-아미노보론산 유도체의 존재하에 약제를 투여함을 특징으로 하여, 프로테아제에 의해 가수분해될 수 있는 펩티드 또는 단백질 약제를 투여하는방법.
    상기식에서 HW,Y 및R은 제1항에서 정의한 바와 같다.
  11. 제10항에 있어서,단백질 또는 펩티드가 로이신 엔케팔린, LH-RH, Tyr-PHe-Met-Arg-Phe-NH2,Tyr-브레디키닌 및 티모포이에틴 Ⅱ로 이루어진 그룹 중 에서 선택되는 방법.
  12. 제10항에 있어서, 펩티드 또는 단백질이 흡수 점막을 통해 투여되는 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019890006223A 1988-05-11 1989-05-10 α-아미노보론산 유도체를 함유하는 펩티드-약제 조성물 KR900017581A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19269088A 1988-05-11 1988-05-11
US192,690 1988-05-11

Publications (1)

Publication Number Publication Date
KR900017581A true KR900017581A (ko) 1990-12-19

Family

ID=22710674

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890006223A KR900017581A (ko) 1988-05-11 1989-05-10 α-아미노보론산 유도체를 함유하는 펩티드-약제 조성물

Country Status (13)

Country Link
EP (1) EP0341661A3 (ko)
JP (1) JPH01319428A (ko)
KR (1) KR900017581A (ko)
AU (1) AU616968B2 (ko)
DK (1) DK229089A (ko)
FI (1) FI892254A (ko)
HU (1) HUT51144A (ko)
IL (1) IL90244A (ko)
MY (1) MY104088A (ko)
NO (1) NO891926L (ko)
NZ (1) NZ229053A (ko)
PT (1) PT90519B (ko)
ZA (1) ZA893517B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673376A1 (fr) * 1991-03-01 1992-09-04 Lefesvre Andre Composition pharmaceutique pour le traitement des tumeurs de kaposi.
CA2125400A1 (en) * 1991-12-18 1993-06-24 Gordon L. Amidon Soybean protein or hydrolyzates in pharmaceutical compositions to protect bioactive peptides from enzymatic inactivation
US6153592A (en) * 1992-11-09 2000-11-28 Port Systems, Llc Enhancing the bioavailability of proteolytically labile therapeutic agents
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
MXPA05002662A (es) 2002-09-09 2005-09-20 Trigen Ltd Sales de metal multivalente de acidos boronicos para el tratamiento de trombosis.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
DE3840452A1 (de) * 1988-12-01 1990-06-07 Hoechst Ag (beta)-amino-boronsaeure-derivate

Also Published As

Publication number Publication date
HUT51144A (en) 1990-04-28
NZ229053A (en) 1990-12-21
NO891926D0 (no) 1989-05-11
MY104088A (en) 1993-11-30
IL90244A0 (en) 1989-12-15
DK229089A (da) 1989-11-12
IL90244A (en) 1993-05-13
FI892254A0 (fi) 1989-05-10
EP0341661A3 (en) 1991-05-02
AU3468289A (en) 1989-11-16
ZA893517B (en) 1991-01-30
PT90519A (pt) 1989-11-30
JPH01319428A (ja) 1989-12-25
DK229089D0 (da) 1989-05-10
NO891926L (no) 1989-11-13
AU616968B2 (en) 1991-11-14
FI892254A (fi) 1989-11-12
EP0341661A2 (en) 1989-11-15
PT90519B (pt) 1994-10-31

Similar Documents

Publication Publication Date Title
KR920703558A (ko) 메타-치환 페닐알라닌 유도체
KR880011199A (ko) 신규 펩타이드 화합물, 그의 제조방법 및 그를 함유하는 약학적 조성물
RU98104253A (ru) Новые опиоидные пептиды
KR890701562A (ko) 면역조절 아자스 피란류
KR930003912A (ko) 울혈성 심장 마비 치료법
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
DE3787061T2 (de) Chelatierte aminosäurezusammensetzungen zur verabreichung an bestimmte gewebestellen.
KR890700601A (ko) 펩티딜아미노디올
KR900006318A (ko) 피페리디닐 벤즈이미다졸
EA199800938A1 (ru) Композиции, содержащие антигрибковый агент и ацетатный буфер
KR890016966A (ko) 신규 항바이러스제
KR860003020A (ko) 디히드로 피리딘과 ace 억제제의 조성물 및 그의 제조방법
KR890701587A (ko) 골 손실에 관련된 질병 치료용 이미다조(1,2-a)(피리
KR920014828A (ko) 신규한 종양 성장-억제 소마토스타틴 동족체, 이 동족체를 함유하는 제약 조성물 및 그 제조방법
KR860006464A (ko) 6-티오크산틴 유도체
SE9002500L (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
KR970025615A (ko) 암 전이 억제제
KR900016238A (ko) 신규 화합물
KR900017581A (ko) α-아미노보론산 유도체를 함유하는 펩티드-약제 조성물
IL83086A0 (en) Stable,injectable solutions of vinca dimer salts
KR900700098A (ko) 발기부전의 치료겸 진단용 플라복세이트 및 그 유도체
KR890012942A (ko) 5-치환된 오르니틴 유도체
KR900014397A (ko) 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
ATE214269T1 (de) Oral anzuwendende flüssige arzneilösung

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid